UBS O'Connor’s NovoCure NVCR Stock Holding History

UBS O'Connor’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-22,782	Closed	-$356K	–	610
2024 Q1	$356K	Buy	+22,782	New	+$335K	0.01%	358

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

UBS O'Connor's NVCR Position: Q2 2024 in Review

UBS O'Connor sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 22,782 shares — an estimated $356K sold.

UBS O'Connor first reported a position in NVCR in Q1 2024 and held it in 1 quarter. The position peaked at $356K in Q1 2024. 236 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

UBS O'Connor reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
UBS O'Connor sold 22,782 NovoCure shares in Q2 2024, an estimated $356K.
UBS O'Connor first reported a position in NovoCure in Q1 2024 and held it in 1 quarter.
UBS O'Connor's NovoCure position peaked at $356K in Q1 2024.
236 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.